Clinical Trials Logo

Type 2 Diabetes Mellitus (T2DM) clinical trials

View clinical trials related to Type 2 Diabetes Mellitus (T2DM).

Filter by:

NCT ID: NCT04943861 Recruiting - HIV Clinical Trials

Human Immunodeficiency Virus (HIV) Food Insecurities

Start date: November 14, 2023
Phase: N/A
Study type: Interventional

The objectives of this study are to better understand how FI (food insecurities) contributes to the development of cardiometabolic comorbidities among PWH (People with HIV) and to test a novel bilingual FI intervention designed to reduce these comorbidities among food insecure PWH. The PI and staff will conduct this study in partnership with the Wake Forest Infectious Diseases Specialty Clinic, one of the largest Ryan White-funded clinics in North Carolina, which serves more than 2,000 PWH annually from a predominantly rural catchment area that includes South Central Appalachia. This area has high rates of both FI and HIV.

NCT ID: NCT04809220 Completed - Clinical trials for Diabetes Mellitus, Type 2

A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes

AWARD-JPN
Start date: April 13, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of 2 doses of dulaglutide in Japanese participants with type 2 diabetes. The study duration is approximately 58 weeks.

NCT ID: NCT04504396 Completed - Clinical trials for Type 2 Diabetes Mellitus (T2DM)

Safety and Efficacy of PB-119 in Subjects With Type 2 Diabetes and Not Well-controlled by Metformin Monotherapy

Start date: June 23, 2020
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 24 once-weekly subcutaneous doses of PB-119 to subjects with type 2 diabetes mellitus (T2DM) not well-controlled by metformin monotherapy.

NCT ID: NCT04504370 Completed - Clinical trials for Type 2 Diabetes Mellitus (T2DM)

Safety and Efficacy of Pegylated Exenatine Injection (PB-119) in Drug-naïve T2DM Subjects

PB119
Start date: April 27, 2020
Phase: Phase 3
Study type: Interventional

A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 24 once-weekly subcutaneous doses of PB-119 in Drug-naïve T2DM Subjects.

NCT ID: NCT04501406 Recruiting - Clinical trials for Nonalcoholic Steatohepatitis

Low-Dose Pioglitazone in Patients With NASH (AIM 2)

Start date: December 15, 2020
Phase: Phase 2
Study type: Interventional

To determine the safety and efficacy of low-dose pioglitazone (15 mg per day) on liver histology in in patients with T2DM with biopsy-proven nonalcoholic steatohepatitis (NASH).

NCT ID: NCT03774394 Completed - Clinical trials for Coronary Artery Disease (CAD)

Impact of Chronic Kidney Disease on Clopidogrel Effects in Diabetes Mellitus

Start date: August 22, 2019
Phase: Phase 4
Study type: Interventional

Patients with diabetes mellitus (DM) and chronic kidney disease (CKD) are at increased risk of atherothrombotic events. Clopidogrel is the most widely used platelet P2Y12 receptor inhibitor in patients with coronary artery disease (CAD). However, despite its benefits, many patients still experience recurrent atherothrombotic events. The proposed study will test the central hypothesis that in DM patients the presence of CKD reduces clopidogrel-mediated P2Y12 inhibitory effects through synergistic mechanisms, which include upregulation of the P2Y12 signaling pathway and impaired clopidogrel metabolism.

NCT ID: NCT03656744 Completed - NAFLD Clinical Trials

A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)

Start date: November 26, 2018
Phase: Phase 2
Study type: Interventional

Randomized, double-blind, placebo-controlled, parallel-group study comparing multiple doses of HTD1801 to placebo.

NCT ID: NCT03604419 Completed - Clinical trials for Type 2 Diabetes Mellitus (T2DM)

Dose-finding of PB-119 Administered Subcutaneously Once Weekly Versus Placebo in Subjects With Type 2 Diabetes

Start date: June 13, 2018
Phase: Phase 2
Study type: Interventional

A phase 2, multicenter study to evaluate the efficacy and safety of twelve once weekly subcutaneous doses of PB-119 to patients with type 2 diabetes mellitus (T2DM) not well-controlled by metformin mono therapy.

NCT ID: NCT03423355 Withdrawn - Clinical trials for Type 2 Diabetes Mellitus (T2DM)

Dapagliflozin Effect on Erythropoiesis and Physical Fitness

Start date: September 2021
Phase: Phase 4
Study type: Interventional

Dapagliflozin effect on erythropoiesis and physical fitness in patients with type 2 diabetes - a randomized, partly double-blinded, controlled, three armed, parallel group, exploratory study

NCT ID: NCT02759107 Completed - Healthy Clinical Trials

A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM)

Start date: May 11, 2016
Phase: Phase 1
Study type: Interventional

The main purposes of this study are to determine: - The safety of tirzepatide and any side effects that might be associated with it. - How much tirzepatide gets into the bloodstream and how long it takes the body to get rid of it. - How tirzepatide affects the levels of blood sugar. This study includes 3 parts (A, B and C). Part A involves a single dose of tirzepatide taken as a subcutaneous (SC) injection just under the skin and will be approximately 10 weeks in duration, including screening. Parts B and C involve 4 doses of tirzepatide taken once weekly (over 4 weeks) as a SC injection just under the skin and is approximately 12-14 weeks in duration, including screening. Each participant will enroll in only one part. This study is for research purposes only, and is not intended to treat any medical condition.